Drug – bio-affecting and body treating compositions – Conjugate or complex of monoclonal or polyclonal antibody,... – Conjugated to proteinaceous toxin or fragment thereof
Patent
1995-06-07
1999-01-12
Achutamurthy, Ponnathapura
Drug, bio-affecting and body treating compositions
Conjugate or complex of monoclonal or polyclonal antibody,...
Conjugated to proteinaceous toxin or fragment thereof
4241781, 4241791, 4241931, 4242771, 4241651, 4242371, 5303911, 5303917, 5303919, A61K 39395, A61K 39385, C07K 1600
Patent
active
058583637
ABSTRACT:
A soluble antibody conjugate comprising an antibody linked to a structure which is recognizable by T-cells and has the ability to direct T-cells to lyse the target cell, which is recognized by the antibody. The conjugate is characterized by the structure being a superantigen. One important mode is a method for the lysis of target cells, wherein the target cells are contacted with a target cell lysis effective amount of the conjugate. The method of lysis is part of a potent treatment regime for cancer, autoimmunity, parasitic infestations and fungal, viral and bacterial infections The specification also describes modes such as the synthesis of the conjugate and pharmaceutical compositions and their manufacture.
REFERENCES:
patent: 4545985 (1985-10-01), Pastan
Dohlsten et al., Proc. Natl. Acad. Sci. USA., vol. 88, pp. 9287-9291, Oct. 1991.
Alber et al., J. Immunol. 144 (190) 4501-4506.
Carlsson et al., Biochem. J. 173 (1978)723-737.
Dohlsten et al., Immunol. 71 (1990) 96-100.
Endo et al., Cancer Res. 48 (1988) 3330-3335.
Fleischer et al., J. Exp. Med. 167 (1988) 1697-1707.
Ghose et al., J. Natl. Cancer Inst. 61 (1979) 657-676.
Hedlund et al., Cell. Immunol 129 (1990) 426-34.
Houghton and Southby, Synth. Commun. 19 (18) (1989) 3199-3209.
Hufnagle et al., Infect. Immun. 59 (1991) 2126-2134.
Ishizaka et al., Cell. Immunol. 118 (1989) 100-107.
Jullien et al., Tetrahedron Letters 29 (1988) 3808-06.
Larsson et al., Int. J. Canc. 42 (1988) 877-82.
Nakatsuji, Kawamura and Okahara, Synthesis (1981), p. 42.
Ochi and Wake, ULCA-Symposium: Celluar Immunmity and the Imuumontherapy of Cancers, Jan. 27-Feb. 3, 1990, Abstract CE 515, p. 109.
Opitz et al., Immunobiol. 160 (1982) 483-453.
Platsoucas et al., (Cell Immunol. 97 (1986) 371-385.
Slama and Rando, Carbohydrate Research 88 (1981) 213-221.
Slama and Rando, Biochemistry 19 (1980) 4595-4600.
White et al., Cell 56 (1989) 27-35.
Biotechnology vol. 7, Jun. 1989 R. Carlson, "Monoclonal Antibodies into the 90 'S".
Legaard et al. Cellular Immunology 135, Jul. 1991 pp. 372-382 The Superantigen Pseudomonas Exotoxin A Requies Additional Functional from accessory cells for T lymphocyte proliferation.
Science vol. 11 May 1990, Philippa Marrack & Johon Kappler, The Staphylococcal Enteroxtoxins and Their relatives --pp. 705-708.
Batra et al (1989) Proc. Natl. Acad. Sci. USA 86:8545-9.
Batra et al (1991) Mol. Cellular Biol. 1/(4):2200-2205.
Kalland et al (1993) Med. Oncol. & Tumor. Pharmacothe, 10(1/2)= 37-47.
"Monoclonal Antibody --Superantigen Fusion Proteins: Tumor Specific Agents for T Cell Based Tumor Therapy"; Dohlsten et al., Proc. Nalt. Acad. Sci. USA., vol. 91, pp. 8945-8949, 1994.
Osband et al (1990) Immunology Today 11(6)= 193-195.
Akerblom Eva
Dohlsten Mikael
Hedlund Gunnar
Lando Peter A.
Achutamurthy Ponnathapura
Pharmacia & UpJohn AB
Ponnaluri P.
LandOfFree
Target specific antibody-superantigen conjugates and their prepa does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Target specific antibody-superantigen conjugates and their prepa, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Target specific antibody-superantigen conjugates and their prepa will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1511934